Pelthos Therapeutics Inc. (PTHS) Form 8-K — May 21, 2026
Pelthos Therapeutics Inc. (PTHS) announced the dismissal of its independent auditor, CBIZ CPAs P.C., and the engagement of Grant Thornton LLP as its new independent registered public accounting firm effective for the fiscal year ending December 31, 2026. The company stated there were no disagreements or reportable events with CBIZ regarding accounting principles or audit scope during the most recent fiscal years. Simultaneously, the company disclosed the formal separation of Francis Knuettel II, who served as Chief Financial Officer, Treasurer, and Secretary, effective April 10, 2026.
Key figures
- Vested RSUs
- 19525
- Severance Pay
- 430000
- Vested Options
- 59500
- Consulting Rate
- 207
- Unused PTOHours
- 110.67
- Severance Months
- 12
- Co BRAReimbursement Months
- 12
Price after filing
Close on the filing date to close N calendar days later (from $27.10). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.